Clinical Trial

Doxycycline for Hereditary Hemorrhagic Telangiectasia

Study Description

Doxycycline for Hereditary Hemorrhagic Telangiectasia

This study will investigate the effectiveness of oral doxycycline for the treatment of recurrent nasal hemorrhage in Hereditary Hemorrhagic Telangiectasia (HHT) subjects. The primary outcome for the trials will be the reduction of epistaxis severity (minutes of bleeding per week). The biological outcomes of interest are the regression of vascular malformations as well as tissue and circulation biomarkers of the relevant mechanistic pathways. A Phase II, randomized double-blind placebo-controlled crossover trial. Approximately 30 subjects with HHT, with moderate-severe recurrent epistaxis will participate in the randomized double-blind placebo-controlled cross over trial. Subject will be treated with a 6-month course of doxycycline 100mg twice daily or placebo twice daily.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Doxycycline Hyclate

Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)

Drug - Placebo

Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)

Additional Information

Official Study Title

Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia

Clinical Trial ID

NCT03397004

ParticipAid ID

nelr7b